Stock Ratings / Health Care / APRE / financials

FBLG (40) XCUR (35) ACXP (39) ENVB (37) ⌘ Pro Terminal →

Aprea Therapeutics Inc. (APRE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.49 -8.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Aprea Therapeutics Inc. (APRE) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $6.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APRE)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How APRE Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.3%	-$12.6M	-$12.9M	-45%
FY 2024	$4.00B	52%	-0.4%	-$13.0M	-$13.6M	-45%
FY 2023	$4.00B	52%	-0.4%	-$14.3M	-$12.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APRE)

✓Walkthrough of APRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.75%📐 HORIZONTAL RANGE

2026-10-30O $0.48H $0.52L $0.46C $0.49VOL 167.6K

RES: $1.22SUP: $0.40SMA50: $0.70SMA200: $0.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APRE Butterfly Map → + Track APRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APRE)

Health Care Rank #596 of 1016 ⚔️ FBLG vs APRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APRE vs. FBLG, XCUR, ACXP, ENVB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aprea Therapeutics Inc. (APRE) ranks #596 by composite RQD confidence (42/100, grade D-) and #925 by equity capitalization ($6.2M). Within this direct 5-issuer industry benchmark cohort, APRE leads on earnings valuation at N/A trailing P/E, while APRE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APRE ACTIVE Aprea Therapeutics Inc.	D-	42/100	—	—	-35.0%	-8.22%	$6.2M	Benchmark Subject
FBLG FibroBiologics Inc.	D-	40/100	—	—	-35.0%	-3.99%	$6.3M	/fblg-vs-apre →
XCUR Exicure Inc.	D-	35/100	—	—	-35.0%	-8.04%	$6.1M	/xcur-vs-apre →
ACXP Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	/acxp-vs-apre →
ENVB Enveric Biosciences Inc.	D-	37/100	—	—	-35.0%	-0.68%	$6.5M	/envb-vs-apre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001781983

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aprea Therapeutics Inc. (APRE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.6M, operating cash flow of -$12.9M, and free cash flow of -$12.9M (+5.0% YoY). On the balance sheet, APRE closed FY2025 with $15.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.6M	-$12.9M	-$12.9M	$15.9M	—
FY2024 (FY)	2024-12-31	$0	-$13.0M	-$13.6M	-$13.6M	$24.0M	—
FY2023 (FY)	2023-12-31	$0	-$14.3M	-$12.2M	-$12.2M	—	—

3. APRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aprea Therapeutics Inc. (NASDAQ: APRE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.49 (-8.22% 1D, market cap $6.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APRE ranks #596 in composite RQD confidence.

How does APRE compare to FBLG and XCUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APRE carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, APRE leads on earnings multiple (N/A) while APRE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APRE?

Per APRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001781983), Aprea Therapeutics Inc. generated $0 in revenue, -$12.6M in net income, and -$12.9M in free cash flow against $15.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APRE trading relative to its 50-day, 200-day, and 52-week technical levels?

APRE last traded at $0.49 (-8.22% on volume of 171,057 shares), positioning the stock -30.00% below its 50-day simple moving average ($0.70) and -34.67% below its 200-day simple moving average ($0.75). Across its 52-week range of $0.41 to $1.49, APRE sits at the 7.4% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.55).